A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Talquetamab (Primary) ; Talquetamab (Primary) ; Recombinant human serum albumin
- Indications Multiple myeloma
- Focus First in man; Registrational; Therapeutic Use
- Acronyms MonumenTAL-1
- Sponsors Janssen Research & Development; Janssen-Cilag
- 28 Jun 2024 Planned number of patients changed from 450 to 480.
- 14 Jun 2024 According to Janssen media release, the data from this trial featured in a poster presentation at the 2024 European Hematology Association (EHA) Congress.
- 14 Jun 2024 Results presented in Janssen Pharmaceuticals media release.